Skip to main content

Market Overview

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWRentered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH.

  • Under the pact, Arrowhead would get an upfront payment of $120 million and is in line for an extra $30 million to start a Phase 2 trial and another $100 million if Phase 2 is successful and leads to a Phase 3.
  • Arrowhead is also eligible for additional milestone payments, including up to $190 million at the first commercial sale and $590 million in sales-related milestone payments.
  • The drug candidate ARO-HSD is currently in an early-to-mid stage trial for nonalcoholic steatohepatitis (NASH).
  • GSK will receive an exclusive license to develop and sell ARO-HSD in all territories except Greater China, which Arrowhead will retain.
  • Arrowhead said it is also eligible to receive tiered royalties on net product sales.
  • Price Action: ARWR shares closed lower by 2.57% at $69.28, while GSK closed 0.72% lower at $41.29 on Monday.

Related Articles (ARWR + GSK)

View Comments and Join the Discussion!

Posted-In: Briefs Non Alcoholic steatohepatitisBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at